Data, Data, Everywhere, But How Much Of It Makes A Real Difference?

Philips Makes A Case For The Value Approach

Dec 11 2018

• By Ashley Yeo

Listen to this article

Having a single patient's complete health care information all in one place was a dream that US visionaries began to talk up around a decade ago. The idea was that fast, electronic support for doctors would aid clinical decision making and efficiency. Ten years on, there is still much work to do before the dream is realized, says Philips' Carla Kriwet. But a solution is within reach.

hand touching screen with medical data — • Source: Shutterstock

Doctors ostensibly have a single, clear task – easy to describe maybe, but usually anything but to deliver. And the two questions they need answers to have never changed: what is the next best thing to do for the patient and what are the risks associated with that course of action? This is what they require, yet the device technologies and data intelligence offerings available are still not delivering the targeted answers they need for the patient sat before them.

Carla Kriwet, CEO of Connected Care and Health Informatics for Philips Healthcare, told In Vivo that in spite of...

More from Outlook Archive

Big Three Lead From The Front With Medtech Back On Solid Growth Footing
Dec 13 2022
• By Ashley Yeo
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Infographic: Top 100 Pharma Companies
Dec 13 2022
• By Lucie Ellis-Taitt
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Pfizer Leads An Unusual Year For The Scrip 100
Dec 13 2022
• By Jessica Merrill
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down
Dec 12 2022
• By Jo Shorthouse
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.

More from Outlook 2024

Scrip 100: By The Numbers
Dec 06 2023
• By Lucie Ellis-Taitt and Kosh Naran
Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.
Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way
Dec 06 2023
• By Ashley Yeo
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
Outlook 2024: Biopharma Embraces New Markets And New Tech
Dec 06 2023
• By Lucie Ellis-Taitt
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?